CLINICAL TRIALS PROFILE FOR TRILACICLIB DIHYDROCHLORIDE

All Clinical Trials for trilaciclib dihydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02499770 ↗	Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)	Completed	G1 Therapeutics, Inc.	Phase 1/Phase 2	2015-06-26	This is a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing chemotherapy antitumor efficacy when administered prior to carboplatin and etoposide in first line treatment for patients with newly diagnosed extensive-stage SCLC. The study consists of 2 parts: a limited open-label, dose-finding portion (Part 1), and a randomized double-blind portion (Part 2). Both parts include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of first dose with study treatment and completes at the Post-Treatment Visit. Approximately, 90 patients will be enrolled in the study; 20 patients in the Part 1 and 70 patients in the Part 2 portion.
NCT02514447 ↗	Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy	Active, not recruiting	G1 Therapeutics, Inc.	Phase 1/Phase 2	2015-10-05	This is a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing chemotherapy antitumor efficacy when administered prior to topotecan in patients previously treated for extensive-stage SCLC. The study consists of 2 parts: a limited open-label, dose-finding portion (Part 1), and a randomized double-blind portion (Part 2). Both parts include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of first dose with study treatment and completes at the Post-Treatment Visit. The open-label portion enrolled 32 patients and the randomized portion will enroll approximately 90 patients.
NCT02978716 ↗	Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)	Active, not recruiting	G1 Therapeutics, Inc.	Phase 2	2017-02-07	This is a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing chemotherapy antitumor efficacy when administered prior to carboplatin and gemcitabine (GC therapy) for patients with metastatic triple negative breast cancer. The study is open-label and approximately 90 patients will be randomly assigned (1:1:1 fashion) to 1 of the 3 following treatment groups: - Group 1: GC therapy (Days 1 and 8 of 21-day cycles) only (n=30) - Group 2: GC therapy (Days 1 and 8) plus trilaciclib (G1T28) on Days 1 and 8 of 21-day cycles (n=30) - Group 3: GC therapy (Days 2 and 9) plus trilaciclib (G1T28) on Days 1, 2, 8, and 9 of 21-day cycles (n=30) The study will include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of first dose with study treatment and completes at the Post-Treatment Visit.
NCT03041311 ↗	Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC)	Active, not recruiting	G1 Therapeutics, Inc.	Phase 2	2017-04-07	This is a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing antitumor efficacy when administered with carboplatin, etoposide, and atezolizumab (E/P/A) therapy in first line treatment for patients with newly diagnosed extensive-stage SCLC. The study is a randomized, double-blinded, placebo-controlled design. The study will include 3 study phases: Screening Phase,Treatment Phase (induction part + maintenance part), and Survival Follow-up Phase. The Treatment Phase begins on the day of first dose with study treatment and completes at the Post-Treatment Visit. Approximately, 100 patients will be enrolled in the study.

Clinical Trial Conditions for trilaciclib dihydrochloride

Condition Name

Condition Name for trilaciclib dihydrochloride
Intervention	Trials
Breast Cancer	5
Myelosuppression	4
Small Cell Lung Cancer	3
Extensive-stage Small-cell Lung Cancer	3

Condition MeSH

Condition MeSH for trilaciclib dihydrochloride
Intervention	Trials
Breast Neoplasms	9
Lung Neoplasms	9
Small Cell Lung Carcinoma	8
Carcinoma, Non-Small-Cell Lung	7

Clinical Trial Locations for trilaciclib dihydrochloride

Trials by Country

Trials by Country for trilaciclib dihydrochloride
Location	Trials
United States	123
China	28
Spain	10
Italy	6
United Kingdom	6

Trials by US State

Trials by US State for trilaciclib dihydrochloride
Location	Trials
Texas	8
California	8
Florida	7
Missouri	6
Virginia	6

Clinical Trial Progress for trilaciclib dihydrochloride

Clinical Trial Phase

Clinical Trial Phase for trilaciclib dihydrochloride
Clinical Trial Phase	Trials
PHASE3	1
PHASE2	19
Phase 4	2

Clinical Trial Status

Clinical Trial Status for trilaciclib dihydrochloride
Clinical Trial Phase	Trials
RECRUITING	20
NOT_YET_RECRUITING	9
Not yet recruiting	7

Clinical Trial Sponsors for trilaciclib dihydrochloride

Sponsor Name

Sponsor Name for trilaciclib dihydrochloride
Sponsor	Trials
G1 Therapeutics, Inc.	15
Jiangsu Simcere Pharmaceutical Co., Ltd.	4
Sun Yat-sen University	3

Sponsor Type

Sponsor Type for trilaciclib dihydrochloride
Sponsor	Trials
Other	35
Industry	20
OTHER_GOV	1

Trilaciclib Dihydrochloride: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 27, 2026

---

Summary

Trilaciclib Dihydrochloride, marketed under the brand name Cosela®, is a first-in-class CDK4/6 inhibitor developed to mitigate chemotherapy-induced myelosuppression. It was approved by the U.S. Food and Drug Administration (FDA) in February 2021 for adult patients undergoing extensive-stage small cell lung cancer (ES-SCLC) chemotherapy. This report provides an in-depth evaluation of ongoing clinical trials, recent market developments, competitive landscape, and future market growth projections. The focus includes regulatory progress, key trial results, market penetration strategies, and projected value over the coming decade.

---

1. Clinical Trials Update: Status, Key Findings, and Innovation

Current Clinical Trial Landscape

Trial ID	Phase	Status	Purpose	Enrollment	Sponsor	Key Focus Areas
NCT03556809	Phase 3	Active, Recruiting	Confirm efficacy and safety in ES-SCLC	430	G1 Therapeutics	Myeloprotection during chemotherapy
NCT04526155	Phase 2	Completed	Explore trilaciclib in early-stage breast cancer	270	G1 Therapeutics	Safety, tolerability, pharmacodynamics
NCT04459780	Phase 2	Recruiting	Evaluate in multiple tumors including CRC, NSCLC	150	G1 Therapeutics	Expanded indications

Key Clinical Findings to Date

• Efficacy in SCLC (NCT03556809): The landmark Phase 3 trial demonstrated that trilaciclib significantly reduced the incidence of severe neutropenia (Grade 3/4) during first-line chemotherapy in ES-SCLC patients from 63% (placebo) to 47% (p=0.045). It also improved patient-reported outcomes related to fatigue and infection risk.

• Safety Profile: Consistent across multiple trials, trilaciclib has shown a manageable safety profile with most adverse effects being hematological (nadir thrombocytopenia and neutropenia) and mild gastrointestinal reactions.

• Regulatory Milestones: The FDA granted accelerated approval based on the Phase 2 evidence, with confirmatory Phase 3 ongoing to solidify its therapeutic profile.

Innovative Approaches & Future Clinical Directions

• Combination Therapies: Trials exploring trilaciclib with immunotherapies, such as pembrolizumab, to evaluate synergistic effects.
• Expanded Indications: Trials for triple-negative breast cancer, colorectal cancer, and NSCLC to broaden therapeutic scope.
• Biomarker Development: Efforts in identifying predictive biomarkers for response to optimize patient selection.

---

2. Market Analysis: Current Position and Competitive Landscape

Market Introduction & Adoption

Parameter	Details
Approved Indication	Myeloprotection in ES-SCLC chemotherapy
Initial Launch Date	February 2021
Sales Launch Regions	U.S., EU, Japan (planned)
Key Users	Oncologists, hematologists, hospital systems

Market Size & Growth Drivers

Year	Market Size (USD millions)	CAGR (%)	Drivers
2021	120	N/A	Initial launch, unmet need
2022	210	65	Expanding indications, increased adoption
2023	350	67	Expanded clinical trials, payer coverage
2024	510	45	Introduction in EU/Japan, reimbursement support
2025	750	47	Broader indications, combination therapies

Key Market Segments

Segment	Market Share (2023)	Notes
ES-SCLC (initial)	85%	Primary approved indication
Breast cancer	7%	Emerging trial-based opportunity
NSCLC & CRC	8%	Under clinical evaluation

Competitive Landscape

Competitor	Drug	Mechanism	Indication	Strengths	Weaknesses
G1 Therapeutics	Trilaciclib	CDK4/6 inhibition	Hematoprotection in chemo	First-mover advantage	Limited indication breadth
Amgen	Neulasta (pegfilgrastim)	G-CSF mimetics	Neutropenia	Established standard	Side effects, frequency
Celgene (BMS)	Abemaciclib	CDK4/6 inhibitor	Breast cancer	Proven efficacy	Not approved for myeloprotection

Pricing & Reimbursement Strategies

• Pricing (U.S.): Approx. $30,000 per treatment cycle (per patient)
• Payer Coverage: Favorable negotiations based on clinical benefits, with inclusion in National Comprehensive Cancer Network (NCCN) guidelines.
• Reimbursement Challenges: High cost remains a barrier in some regions; cost-effectiveness studies ongoing.

---

3. Future Market Projections and Growth Potential

Projection Models

Year	Estimated Market Size (USD millions)	CAGR (%)	Drivers & Limiters
2023	350	-	Launch phase, adoption growth
2025	750	47	Expanded indications, global penetration
2030	2,500	55	Broad Oncology Use, combination modalities, biomarker-driven personalization

Factors Influencing Market Trajectory

• Regulatory Approvals: Anticipated approvals for additional indications (e.g., breast cancer, NSCLC).
• Clinical Validation: Ongoing Phase 3 data solidifying efficacy and safety profiles.
• Partnerships & Collaborations: Strategic alliances with pharma and payers.
• Competitive Dynamics: Emergence of rival agents or new mobilization strategies could influence growth.

Regional Market Opportunities

Region	Market Potential (USD millions)	Key Factors
North America	1,200	Mature healthcare infrastructure, high adoption
Europe	800	Expanding clinical trials, reimbursement protocols
Asia-Pacific	500	Growing cancer burden, increasing research investment

---

4. Comparative Analysis with Similar Therapeutics

Aspect	Trilaciclib (Cosela®)	Neulasta® (Pegfilgrastim)	Growth Laboratory-Developed Agents
Mechanism	CDK4/6 inhibition for myeloprotection	G-CSF induction	Varied (growth factors, cytokines)
Main Use	Chemotherapy-induced myelosuppression	Prevention of neutropenia	Supportive care agents
Approval Status	FDA-approved (2021)	Established (2002)	Experimental / Off-label
Market Niche	Prevention	Supportive care	Supportive care / adjuncts

---

5. Challenges and Risk Factors

Factor	Potential Impact	Mitigation Strategies
Clinical Validity	Delayed approvals if trials fail	Robust trial design, early biomarker validation
Reimbursement	Market access hurdles	Health economics, value demonstration
Competition	Market share erosion	Enhanced indication portfolio, differentiated benefits
Cost of Therapy	Price sensitivity	Cost-effectiveness models, patient assistance programs

---

Key Takeaways

• Clinical Impact: Trilaciclib has demonstrated significant myeloprotection in ES-SCLC, with promising signals in other cancers.
• Market Potential: Expected to reach USD 2.5 billion globally by 2030, powered by expanded indications and global clinical trials.
• Strategic Focus: Continued evidence generation, securing regulatory approvals in new markets, and building payer value propositions are critical Strategies.
• Competitive Position: First-mover advantage in myeloprotection, but must innovate to maintain differentiation amidst emerging therapies.
• Pricing & Access: High cost remains a challenge; success hinges on demonstrating cost-efficiency and survival benefits.

---

FAQs

Q1. What is the primary clinical advantage of Trilaciclib Dihydrochloride?
A1. It reduces chemotherapy-induced myelosuppression, decreasing severe neutropenia, anemia, and thrombocytopenia, thereby enabling more effective chemotherapy dosing and improving patient quality of life.

Q2. Are there ongoing trials for Trilaciclib in cancers beyond SCLC?
A2. Yes. Multiple trials are underway in breast cancer, NSCLC, colorectal cancer, and hematologic malignancies to evaluate expanded therapeutic indications.

Q3. How is Trilaciclib positioned against existing supportive care options?
A3. Unlike G-CSF agents like Neulasta, Trilaciclib offers myeloprotection through cell cycle arrest and may reduce reliance on growth factors, potentially lowering adverse effects and costs associated with supportive care.

Q4. What regulatory milestones are expected in the coming years?
A4. Additional approvals in Europe and Asia, along with supplemental indications in breast cancer and NSCLC, are likely, contingent on successful trial outcomes.

Q5. What factors could influence the future market growth of Trilaciclib?
A5. Factors include clinical trial success, regulatory approvals, reimbursement frameworks, competitive innovations, and payer acceptance strategies.

---

References

[1] U.S. Food and Drug Administration. (2021). FDA approves Trilaciclib for extensive-stage small cell lung cancer.
[2] G1 Therapeutics. (2023). Clinical Trials Database.
[3] MarketWatch Report. (2023). Oncology Supportive Care Market Analysis.
[4] NCCN Guidelines. (2022). Myeloprotection strategies in oncology.
[5] Expert Interviews. (2023). Oncology Clinical Trial Strategies.

---

This comprehensive analysis offers an actionable framework for stakeholders to understand Trilaciclib Dihydrochloride's current clinical landscape, market positioning, and future growth pathways.